article Open AccessTop 1% cited
Mechanisms of Resistance to Crizotinib in Patients with <i>ALK</i> Gene Rearranged Non–Small Cell Lung Cancer
Clinical Cancer Research · 2012 · Vol. 18(5) · pp. 1472–1482
Robert C. Doebele✉(University of Colorado Anschutz Medical Campus)Amanda Pilling(University of Colorado Anschutz Medical Campus)Dara L. Aisner(University of Colorado Anschutz Medical Campus)Tatiana G. Kutateladze(University of Colorado Anschutz Medical Campus)Anh T. Le(University of Colorado Anschutz Medical Campus)Andrew Weickhardt(University of Colorado Anschutz Medical Campus)Kimi Kondo(University of Colorado Anschutz Medical Campus)Derek J. Linderman(University of Colorado Anschutz Medical Campus)Lynn E. Heasley(University of Colorado Anschutz Medical Campus)Wilbur A. Franklin(University of Colorado Anschutz Medical Campus)Marileila Varella‐Garcia(University of Colorado Anschutz Medical Campus)D. Ross Camidge(University of Colorado Anschutz Medical Campus)
Abstract
Crizotinib resistance in ALK(+) NSCLC occurs through somatic kinase domain mutations, ALK gene fusion CNG, and emergence of separate oncogenic drivers.
Lung Cancer Treatments and MutationsLung Cancer Research StudiesPI3K/AKT/mTOR signaling in cancerCrizotinibAnaplastic lymphoma kinaseCancer researchLung cancerALK inhibitorKRASMedicineMutationGene rearrangementFusion gene
MeSH terms
CrizotinibAnaplastic Lymphoma KinaseCarcinoma, Non-Small-Cell LungCell LineHumansLung NeoplasmsModels, MolecularMutationProto-Oncogene ProteinsPyrazolesPyridinesTranslocation, GeneticOncogene Proteins, FusionProto-Oncogene Proteins p21(ras)Protein Structure, Tertiary
Citations
1,061
FWCI
97.91
field-weighted impact
References
44
Percentile
100%
vs. same field & year
Citations per year
References
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Science Translational Medicine · 2011 · 3,534 citations
Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
PLoS Medicine · 2005 · 3,519 citations
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
Journal of Clinical Oncology · 2008 · 3,206 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.